Research has proposed the development of GM-CSF−/− CAR-T cells (ablation of GM-CSF in CAR-T cells) as a potential strategy to reduce the CRS and neurotoxicity associated with CAR-T therapy (89). The gene discussed is CSF2; the disease is congenital rubella syndrome.